| Dr Pragnesh Jitendrabhai Patel, MD | |
|
15555 Creek Bend Dr Ste 200, Sugar Land, TX 77478 | |
| (832) 707-5978 | |
| Not Available |
| Full Name | Dr Pragnesh Jitendrabhai Patel |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 15 Years |
| Location | 15555 Creek Bend Dr Ste 200, Sugar Land, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265787360 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | Q4242 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sugar Land Surgical Hospital Llp | Sugar land, TX | Hospital |
| Houston Methodist Sugarland Hospital | Sugar land, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dr Adeeb Associated | 9436417672 | 6 |
News Archive
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, Eq, 1.4 mg/0.36 mg and 5.7 mg/1.4 mg Base. Actavis' ANDA product is a generic version of Orexo's Zubsolv, which is a partial opioid agonist indicated for the maintenance treatment of opioid dependence.
Heart patients may experience "a lot less" trauma with a new invention to mend leaky valves with minimum cutting, says inventor James Gammie, MD, an associate professor at the University of Maryland (UM) School of Medicine.
The Mount Sinai Medical Center has taken the lead in developing the largest treatment and monitoring program for emergency responders, recovery workers, residents, and area workers who were affected by the terrorist attacks in New York City on September 11, 2001.
Natalie Ciaccio, a fourth-year graduate student researcher in the Department of Pharmaceutical Chemistry at the University of Kansas, is investigating what might be an ideal target for anti-cancer drug therapy, and she is focusing her work on brain tumors specifically.
› Verified 8 days ago
| Entity Name | Mcallen Hospitalist Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356361976 PECOS PAC ID: 9830113836 Enrollment ID: O20060117001076 |
News Archive
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, Eq, 1.4 mg/0.36 mg and 5.7 mg/1.4 mg Base. Actavis' ANDA product is a generic version of Orexo's Zubsolv, which is a partial opioid agonist indicated for the maintenance treatment of opioid dependence.
Heart patients may experience "a lot less" trauma with a new invention to mend leaky valves with minimum cutting, says inventor James Gammie, MD, an associate professor at the University of Maryland (UM) School of Medicine.
The Mount Sinai Medical Center has taken the lead in developing the largest treatment and monitoring program for emergency responders, recovery workers, residents, and area workers who were affected by the terrorist attacks in New York City on September 11, 2001.
Natalie Ciaccio, a fourth-year graduate student researcher in the Department of Pharmaceutical Chemistry at the University of Kansas, is investigating what might be an ideal target for anti-cancer drug therapy, and she is focusing her work on brain tumors specifically.
› Verified 8 days ago
| Entity Name | Seton Family Of Doctors |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588997233 PECOS PAC ID: 0941333280 Enrollment ID: O20100806000260 |
News Archive
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, Eq, 1.4 mg/0.36 mg and 5.7 mg/1.4 mg Base. Actavis' ANDA product is a generic version of Orexo's Zubsolv, which is a partial opioid agonist indicated for the maintenance treatment of opioid dependence.
Heart patients may experience "a lot less" trauma with a new invention to mend leaky valves with minimum cutting, says inventor James Gammie, MD, an associate professor at the University of Maryland (UM) School of Medicine.
The Mount Sinai Medical Center has taken the lead in developing the largest treatment and monitoring program for emergency responders, recovery workers, residents, and area workers who were affected by the terrorist attacks in New York City on September 11, 2001.
Natalie Ciaccio, a fourth-year graduate student researcher in the Department of Pharmaceutical Chemistry at the University of Kansas, is investigating what might be an ideal target for anti-cancer drug therapy, and she is focusing her work on brain tumors specifically.
› Verified 8 days ago
| Entity Name | Dr Adeeb Associated |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326587643 PECOS PAC ID: 9436417672 Enrollment ID: O20171218001914 |
News Archive
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, Eq, 1.4 mg/0.36 mg and 5.7 mg/1.4 mg Base. Actavis' ANDA product is a generic version of Orexo's Zubsolv, which is a partial opioid agonist indicated for the maintenance treatment of opioid dependence.
Heart patients may experience "a lot less" trauma with a new invention to mend leaky valves with minimum cutting, says inventor James Gammie, MD, an associate professor at the University of Maryland (UM) School of Medicine.
The Mount Sinai Medical Center has taken the lead in developing the largest treatment and monitoring program for emergency responders, recovery workers, residents, and area workers who were affected by the terrorist attacks in New York City on September 11, 2001.
Natalie Ciaccio, a fourth-year graduate student researcher in the Department of Pharmaceutical Chemistry at the University of Kansas, is investigating what might be an ideal target for anti-cancer drug therapy, and she is focusing her work on brain tumors specifically.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Pragnesh Jitendrabhai Patel, MD 2117 Dickey Pl, Houston, TX 77019-6009 Ph: (327) 075-9788 | Dr Pragnesh Jitendrabhai Patel, MD 15555 Creek Bend Dr Ste 200, Sugar Land, TX 77478 Ph: (832) 707-5978 |
News Archive
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, Eq, 1.4 mg/0.36 mg and 5.7 mg/1.4 mg Base. Actavis' ANDA product is a generic version of Orexo's Zubsolv, which is a partial opioid agonist indicated for the maintenance treatment of opioid dependence.
Heart patients may experience "a lot less" trauma with a new invention to mend leaky valves with minimum cutting, says inventor James Gammie, MD, an associate professor at the University of Maryland (UM) School of Medicine.
The Mount Sinai Medical Center has taken the lead in developing the largest treatment and monitoring program for emergency responders, recovery workers, residents, and area workers who were affected by the terrorist attacks in New York City on September 11, 2001.
Natalie Ciaccio, a fourth-year graduate student researcher in the Department of Pharmaceutical Chemistry at the University of Kansas, is investigating what might be an ideal target for anti-cancer drug therapy, and she is focusing her work on brain tumors specifically.
› Verified 8 days ago
Vandana Khera, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 18717 University Blvd Bldg 2, Suite 105, Sugar Land, TX 77479 Phone: 281-208-3322 Fax: 281-208-3393 | |
Susan Vijayan Mathew, DO Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 16811 Southwest Fwy Fl 3, Sugar Land, TX 77479 Phone: 281-275-0897 | |
Saif K Altaie, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 16655 Southwest Fwy, Sugar Land, TX 77479 Phone: 281-274-7000 | |
Priya N. Oolut, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 16659 Southwest Fwy Ste 421, Sugar Land, TX 77479 Phone: 281-325-0005 Fax: 713-512-2247 | |
Dr. Htut Kyaw Win, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 16605 Southwest Fwy Ste 360, Sugar Land, TX 77479 Phone: 713-790-0841 Fax: 713-790-9963 | |
Cathlyn Anderson, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 15200 S Us 59 Highway Suite 360, Sugar Land, TX 75075 Phone: 832-237-3500 Fax: 832-237-0200 | |
Angela Denise Mcgee, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 11555 University Blvd, Sugar Land, TX 77478 Phone: 713-442-9100 |